Sign In
Buy STIM
$1.20
-0.0300 (-2.44%)
At Close: Jun 22, 2026
Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call
08:30am, Tuesday, 20'th Feb 2024
MALVERN, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
08:32am, Monday, 12'th Feb 2024
Advancements provide workflow efficiencies for NeuroStar® TMS providers Advancements provide workflow efficiencies for NeuroStar® TMS providers
NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
08:28am, Tuesday, 06'th Feb 2024
MALVERN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results
08:30am, Monday, 08'th Jan 2024
MALVERN, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of tran
Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference
04:15pm, Wednesday, 15'th Nov 2023
MALVERN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
Neuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call
08:30am, Tuesday, 24'th Oct 2023
MALVERN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve th
Neuronetics: Large Losses May Be Repelling Investors
05:26pm, Wednesday, 06'th Sep 2023
Neuronetics is currently facing challenges from increased competition and a difficult macro environment, which is impacting growth and profitability. While market conditions appear to have stabilized
Neuronetics, Inc. (STIM) Q2 2023 Earnings Call Transcript
12:59pm, Tuesday, 08'th Aug 2023
Neuronetics, Inc. (NASDAQ:STIM ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 PM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer St
Neuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call
08:30am, Tuesday, 25'th Jul 2023
MALVERN, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve th
Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference
04:30pm, Wednesday, 24'th May 2023
MALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or “Neuronetics”), a commercial stage medical technology company with a strategic vision of trans
Neuronetics, Inc. (STIM) Q1 2023 Earnings Call Transcript
12:13pm, Saturday, 13'th May 2023
Neuronetics, Inc. (NASDAQ:STIM ) Q1 2023 Earnings Conference Call May 13, 2023 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Stev
Neuronetics to Present at the JMP Securities Life Sciences Conference
05:00pm, Tuesday, 09'th May 2023
MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical technology company with a strategic vision of transform
Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call
08:30am, Tuesday, 25'th Apr 2023
MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve t
Cannell Capital Now Owns 11.03% of Neuronetics
10:21pm, Thursday, 23'rd Mar 2023
Fintel reports that Cannell Capital has filed a 13D/A form with the SEC disclosing ownership of 3.13MM shares of Neuronetics Inc (STIM).
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
09:47am, Tuesday, 07'th Mar 2023
Neuronetics (STIM) delivered earnings and revenue surprises of 30.23% and 9.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
